Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR442168 (BTK inhibitor) in relapsing multiple sclerosis
NCT03889639Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of tolebrutinib in multiple sclerosis (MS), sponsored by Sanofi. Started Mar 2019; status: completed.
02
Drugs
tolebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03889639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03889639.